Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good afternoon Karin, I do not have knowledge in the matter therefore cannot say anything about. Common sense tells me something is not "right". Dr Allen sounded positive and confident. I am waithing what the Co. has to say withing few weeks ????.......
Janet...That placebo response is the toughest problem to overcome in trials. Many trials are showing the placebo responses to be just as or more effective than drugs on trial.
Today's drop is just the start. Will drop much more the following days. Wait to get in at 0.02 - 0.04
Not the NEWS we where expecting!!!
Stem Cell Therapeutics Corp. Announces Top-Line Results for the Modified REGENESIS Phase IIb Stroke Trial
CALGARY, ALBERTA, May 25, 2010 (MARKETWIRE via COMTEX News Network) --
Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE: SSS) announced today the top-line results for the modified REGENESIS-Phase IIb stroke trial. The modified REGENESIS- Phase IIb trial, a placebo controlled, double blinded, 3:1 randomized clinical study, enrolled 96 patients with acute ischemic stroke between August 2009 and January 24, 2010. SCT reports that the top-line primary endpoint results for this Phase IIb clinical trial of NTx(R)-265 in acute stroke showed that there was substantial improvement in the primary endpoint absolute change in NIHSS in both placebo treated patients and those receiving NTx(R)-265 with no statistical differences between the groups.
"The profile and magnitude of the placebo response is extremely surprising and merits further examination" said Dr. Alan Moore, CEO and President of Stem Cell Therapeutics. "We are currently conducting a validation review process of the full trial. We expect to report on the outcome of this within the next 2-3 weeks, together with results from a number of secondary endpoints such as modified Rankin and Barthel index, which may provide an alternative to NIHSS as a pathway forwards."
The results show that NTx(R)-265 was well tolerated in treated patients with no adverse affect on mortality. Of the 96 patients enrolled in the trial, 72 patients were administered a course of NTx(R)-265, sequential administration of human chorionic gandotropin (hCG) followed by erythropoietin (EPO), with the first dose at 24-48 hours after stroke onset while 24 patients were treated with placebo. All patients were then monitored for 90 days. The top-line data show that the NTx(R)-265 treated group showed a drop of 6.3 +/- 0.5 NIHSS compared to placebo drop of 7.3 +/- 0.9 NIHSS. This difference was not statistically significant. Additionally, none of the individual dose groups showed a statistically significant effect compared to placebo.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.
For further information on Stem Cell Therapeutics Corp., visit www.stemcellthera.com.
These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:Stem Cell Therapeutics Corp.Alan Moore, PhDPresident and CEO403-245-5495 ext.224amoore@stemcellthera.comStem Cell Therapeutics Corp.Angelika Goncalves DaSilvaOperations Manager403-245-5495 ext. 221adasilva@stemcellthera.comwww.stemcellthera.com
SOURCE: Stem Cell Therapeutics Corp.
mailto:amoore@stemcellthera.com mailto:adasilva@stemcellthera.com http://www.stemcellthera.com
Good morning Brian34, yes Canadian market is closed on monday
Wishing a nice weekend
janet
There's a huge gap between $3,000 and $45,000 per treatment.
It's back from that low a few days ago. Crazy drop.
What did happen in the morning was so very much DISHONEST!!!
Disgusting what "GREED" makes some peoples do !!!
From Stock House, from a respected poster rjc:
Thanks for the following AGM note from CSv2 at http://www.stockhouse.com/Bullboards/MessageDetail.aspx?p=0&m=28259940&l=0&r=0&s=SSS&t=LIST
and for the note from yesoilers at
http://www.stockhouse.com/Bullboards/MessageDetail.aspx?p=0&m=28260525&l=0&r=0&s=SSS&t=LIST
that I have found since I got home (hope I didn’t miss anybody) I’ll build on those.
Alan gave the normal investor presentation to us that covers already published information. I’ll comment on a couple of things from the presentation.
Alan gave the presentation based on his investor presentation slide set. Slide 6 showed what today’s share price antics messed up … his “surprise” AGM announcement that we would be getting the Trial results next Tuesday. He had to get that information out earlier today to help explain that the price action had nothing to do with a leak of any sort.
He explained that the particular rule that limited the Trial enrollment in India (that had previously been presented as a guideline) was that 25% of the Trial participation had to come from outside of India. What we ended up with was 93 patients enrolled in India and 3 patients enrolled in Canada.
There was a brief mention that the selling price of the NTx-265 (hCG + EPO) product was still up in the air, with a suggestion that $45,000 for the treatment was in line with current pharmaceutical pricing practices. In earlier company valuation estimates, Alan had been using a very conservative $3,000 for the treatment. Feel free to pick your own number at this point for budgeting. The eventual pricing responsibility will likely be in the hands of a future partner. In an earlier company presentation, the stroke market had been estimated at $1 billion for North America, and $1.5 billion for the world (per year). These numbers had been based on $3,000 per treatment.
Some stuff that we had already seen was shown again on Traumatic Brain Injury (TBI), and that was the rat data. One part of the story here was that TBI was much more severe a problem to fix, generally, than was stroke (and had no “standard of care” at all. In this pre-clinical Trial, the rats were subjected to brain impact while they were sedated. A functional scale (0 to 12) was used to measure function where 0 to 2 represented degrees of normal, and 12 represented dead. Over the first 2 days, the rats moved from a score of 2, to a new score of 10 or 11. At day 21, the score of the treated rats had moved back to 2 … where they started. Pretty impressive. The rat stroke results turned out to be predictive of human response. We’ll soon find out if the rat TBI results are also predictive of human response in the upcoming 10 patient initial Trial with human TBI patients (with the same treatment being used as in the stroke Trial).
Our Phase III stroke protocol will be based on what we learn from the Phase II stroke results. The end of Phase II meeting with the FDA will be held in H2 … July or later. An “end of Phase II” meeting is conducted to discuss (with the FDA) what an acceptable Phase III protocol would look like.
All of the SCT personnel there seemed to be proud of where they were at in the development program. In addition to Alan, I spoke to Jackie who looks after Intellectual Property, Barry who does finance, Allen who looks after the clinical programs, and a couple of other board members.
rjc
That will be interesting to see. Thanks for the info. ;)
From Stock House: Someone received an e-mail from the Co.
Alan just replied to my email on as to whats happening.
Its crazy and unfounded. We'll issue a PR as soon as we can today saying there is NO basis for this !!!Cheers Alan
The market is pretty bad all over.
Good morning Karin, as long as it is "manipulation" we should not worry!!!!- The most important is that the Co. will have good news for us........
Well, it is sure going down.
Any idea what is happening here?
Karen thanks for the link...Was wondering why no one was posting on the SCTPF board...
I think we see results this week because of the shareholder meeting this week...CEO is going to want to strut his stuff..
Hoping we see a dollar with results...
Brian
Good morning Karin, so far so god. Hopefully next week we will know more......
Have a great day
janet
It seems we've had another good day here Janet. ;)
You called it right, but, no real surprise here. ;)
Good morning Karin. Looks like we might go up today again.....
Have a great day
janet
TSX:SSS... Nice move today...;)
From Stock House:
Ready for a great week?
CIBC says BUY
https://cibcmr.reutersresearch.com/Views/Viewers/PageViewer.aspx?disablePrintIcon=true&fileExt=pdf&id=40882412&docOrigin=Research
CIBC Consensus Recommendation
BUY
Last Updated
8 May 2010
American Bulls say BUY
http://americanbulls.com/StockPage.asp?CompanyTicker=SSS&MarketTicker=VSE&Typ=S
-Year Signal History
05.07.10 0.4200 Buy
Dundee says BUY
http://research.dundeesecurities.com/Research/SSS042210.pdf
From Stock House post it by pleazu69
Letter from the CEO:
I got the letter today as well. He always sounds so upbeat and encouraging in his PR statements, emails and phone calls. I am getting pretty anxious myself, these 3 weeks are going to feel like 3 months IMO.
here's an excerpt:
"Clearly, a positive outcome for the modified REGENESIS study will be a huge accomplishment for SCT and it's shareholders and a major opportunity for therapeutic development for stroke patients in the future. However, several other ares add value to SCT from our ongoing work in traumatic brain injury (TBI) (Health Canada approved the the new clinical study in January 2010), or the multiple sclerosis clinical program, through to our IP portfolio, where again we have had important new additions this year, and finally our SHRED tax credits which as a public company we cannot cash on an annual basis, but do represent real value to us as a company in the future.
This is truly a major moment in the sun for us as a company, and I thank you, my loyal fellow shareholders for staying with us and supporting us during a period of some uncertainty. I hope to continue, as the head of the Management team, to earn your continued confidence... and I very much appreciate that. Cheers!!
Sincerely.
Alan F. Moore, PhD
President & CEO"
Thanks for the info locks...
Stem Cell Therapeutics Corp. Announces the Completion of the 90 Day Endpoint Period for the Last Patient Enrolled in the Modified REGENESIS Phase IIb Stroke Trial
CALGARY, ALBERTA -- (Marketwire) -- 04/26/10 -- Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE: SSS) is pleased to announce today that the 90- day follow up period for the last patient enrolled in the modified REGENESIS- Phase IIb stroke trial has been reached. The modified REGENESIS- Phase IIb trial, a placebo controlled, double blinded, 3:1 randomized clinical study, enrolled 96 patients with acute ischemic stroke between August 2009 and January 24, 2010. This point in the trial is a major milestone, as it marks the completion of the patient assessment period and the beginning of the process of compilation, data analysis and reporting of top-line primary endpoint results for this key Phase IIb clinical trial of NTx®-265 in acute stroke.
Dr. Alan Moore, President and CEO, commented as follows:
"With the last patient completing their 90-day observation endpoint, the modified REGENESIS- Phase IIb stroke trial enters into the exciting stage of data analysis and the reporting of top-line results. This exhilarating period in the Company's development is the culmination of solid support from the Company's shareholders, management and research and development team. SCT looks forward with great anticipation to the soon to be announced top-line results of the modified REGENESIS- trial as this truly marks a key milestone in the development of this new therapy for stroke patients. With enrollment of the modified Phase IIb stroke trial ended and data analysis commencing top-line results are expected within the next 4 weeks, significantly earlier than the "end of Q2" target that we previously discussed."
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.
These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
Contacts:
Stem Cell Therapeutics Corp.
Alan Moore, PhD
President and CEO
403-245-5495 ext.224
amoore@stemcellthera.com
Stem Cell Therapeutics Corp.
Angelika Goncalves DaSilva
Operations Manager
403-245-5495 ext. 221
adasilva@stemcellthera.com
www.stemcellthera.com
< Return to Press Releases
Articles appearing above are picked up from MarketWire's feed. Stories from this feed are submitted by companies, edited and rereleased as a service of MarketWire.
Sign up for FDLI SmartBrief
Designed specifically for professionals involved in the food and drug industry, FDLI SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition. Learn more
Companies mentioned
•Cell Therapeutics Corp.
Good morning Karin, someone post it this on Stock House:
SSS has submitted it's latest MD & A Discussion document to SEDAR. They have included a lot of information. A good read and positive.
The document seems to be more detailed than usual which I see as a good sign.
http://www.sedar.com/FindCompanyDocuments.do
Thanks Janet...there's some good news there. ;)
Stem Cell Therapeutics Corp. Announces YearEnd 2009 Financial Results
4/13/2010 5:39:12 PM - Market Wire
CALGARY,ALBERTA, Apr 13, 2010 (MARKETWIRE via COMTEX News Network) --
StemCell Therapeutics Corp. ("SCT") (TSX VENTURE: SSS) today announced itsfinancial results for the period ended December 31, 2009.
OperatingHighlights from 2009 and the period ending April 13, 2010:
-- Presented positive final results for the BETAS Phase IIa clinical safety
study in stroke in February 2009, including all U.S. and Canadian
patient data
-- Received FDA approval to proceed with the modified REGENESIS Phase IIb
acute ischemic stroke trial
-- Initiated and began enrolling patients in India and Canada for the
modified REGENESIS Phase IIb acute ischemic stroke trial
-- Completed enrollment in modified REGENESIS Phase IIb acute ischemic
stroke study; Q1 10
2010 Objectives
-- Report Top-line REGENESIS Phase IIb data; Q2 10
-- Complete preclinical study for hemorrhagic stroke; H2 10
-- Complete 'end of Phase II' meeting with FDA; H2 10
-- Initiate and enroll patients in a Phase IIa TBI clinical study; H1 10
-- Initiate MS clinical Proof-of-Concept study; H2 10
Capital Position
As of December 31, 2009, the workingcapital (current assets minus current liabilities) of the Company was$4,100,869 ($5,803,377 as of December 31, 2008).
Outstandingsecurities as of December 31, 2009 totaled 152,905,004 common shares,34,070,983 common share purchase warrants and 14,012,500 common shareoptions. On April 13, 2010 there were 153,005,004 common shares,33,970,983 common share purchase warrants and 14,012,500 common shareoptions outstanding.
Financial Review
The Company's lossfor the year ended December 31, 2009 decreased by $902,624 to $4,656,893(
.03 per common share) from the loss of $5,559,517 (
.05 per commonshare) reported for the year ended December 31, 2008. The primary reasonfor the decrease in loss was a decrease in general and administrationexpense, management and consulting fees, research and developmentexpenses, professional fees and because there was no deemed interestpaid in the year. The decrease in these expenses was partially offset bythe recording of a foreign exchange loss, as well as a decrease ininterest income and an increase in stock option expense.
Dr. AlanMoore, President & CEO of SCT commented as follows:
"2009was a game-changing year for us as a Company. Working with the FDA andHealth Canada to lift the clinical hold and then completing enrollmentin the key phase IIb modified REGENESIS study were major accomplishmentsputting the Company in a strong position heading into 2010.
Additionally,the commitment that senior management showed to the Company in 2009,through their salary reductions and deferring any bonus payments, hasresulted in us maintaining a strong financial position to complete ourwork in 2010."
About Stem Cell Therapeutics Corp.: Stem CellTherapeutics Corp. is a Canadian public biotechnology company (TSXVENTURE: SSS) focused on the development and commercialization ofdrug-based therapies to treat central nervous system diseases. SCT is aleader in the development of therapies that utilize drugs to stimulate apatient's own resident stem cells. The Company's programs aim to repairneurological function lost due to disease or injury. SCT's extensivepatent portfolio of owned and licensed intellectual property supportsthe potential expansion into future clinical programs in numerousneurological diseases such as traumatic brain injury, multiplesclerosis, Huntington's disease, Alzheimer's disease, and ALS.
Thesesecurities have not been registered under the United States SecuritiesAct of 1933, as amended, or the securities laws of any state, and maynot be offered or sold within the United States or to, or for theaccount or benefit of U.S. persons unless an applicable exemption fromU.S. registration requirements is available.
Except forhistorical information, this press release may contain forward-lookingstatements, which reflect the Company's current expectation regardingfuture events. These forward-looking statements involve risk anduncertainties, which may cause but are not limited to, changing marketconditions, the successful and timely completion of clinical studies,the establishment of corporate alliances, the impact of competitiveproducts and pricing, new product development, uncertainties related tothe regulatory approval process and other risks detailed from time totime in the Company's ongoing quarterly and annual reporting.
TheTSX Venture Exchange does not accept responsibility for the adequacy oraccuracy of this release.
Contacts: Stem Cell TherapeuticsCorp. Alan Moore, PhD President and CEO 403-245-5495 ext.224amoore@stemcellthera.com Stem Cell Therapeutics Corp. AngelikaGoncalves DaSilva Operations Manager 403-245-5495 ext. 221adasilva@stemcellthera.com www.stemcellthera.com
SOURCE: StemCell Therapeutics Corp.
Good morning Janet and anyone else around. ;)
SSS.V is sure looking better than it was last November. It's definitely in a better price range now. And, should go higher. JMO
Hopefully soon Karin,
Have a beautiful day,
janet
The stock will most likely have a pop sometime within the next week since I'm betting his presentation will be well recieved. JMO
Thanks for posting this Janet. ;)
Stem Cell Therapeutics Corp. Announces Dr. Alan Moore's Presentation at the BioFinance 2010 Meeting April 6-8, 2010, Toronto, Canada
CALGARY, ALBERTA, Apr 06, 2010 (MARKETWIRE via COMTEX News Network) --
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT") today announced that Dr. Alan Moore, President CEO of SCT, will be presenting on behalf of SCT at the BioFinance 2010 meeting which is being held in Toronto, Canada, April 6-8, 2010.
Dr. Alan Moore will be speaking at 9:30 a.m., on April 7th, 2010, in the Simcoe Room of the Toronto Marriott Eaton Centre. Dr. Moore's presentation will discuss the progress that SCT has made in 2009 and the future direction that company will pursue in 2010 with its product line.
Dr. Alan Moore, President and CEO of SCT, commented as follows:
"We are excited to have this opportunity to communicate with the BioFinance community on our Company's achievements and the future potential of SCT as we continue our product development.
Our outlook for this year includes:
- Completion of Phase IIb stroke trial patient analysis and announcement of top-line results;- The opportunity to build on our strengths with the initiation of additional clinical programs in Traumatic Brain Injury and Multiple Sclerosis."
About the BioFinance 2010 meeting (http://www.biofinance.ca/): BioFinance 2010 is the leading investor conference in Canada for the life sciences industry. This three-day event brings together key industry players interested in investment opportunities and issues affecting companies in the life sciences sector. Presenting companies will span a range of industries including: biologics, medical devices, drug delivery, vaccines, diagnostics, bio-energy, green technologies, bio materials, industrial biotech, and research services.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.
For further information on Stem Cell Therapeutics Corp., visit www.stemcellthera.com.
These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available. Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
The Stroke Market:
http://www.stemcellthera.com/IR.aspx?section=strokemarket
The Global Burden of Stroke
• Every year, 15 million people worldwide suffer a stroke. Five million die and another five million are left permanently disabled. Disability may include loss of vision and / or speech, paralysis and confusion.
• Globally, stroke is the second leading cause of death above the age of 60 years, and the fifth leading cause of death in people aged 15 to 59 years old.
• Stroke is uncommon in people under 40 years, although it does happen. In young people the most common causes are high blood pressure or sickle cell disease.
• In many developed countries the incidence of stroke is declining even though the actual number of strokes is increasing because of the ageing population.
• In the developing world, however, the incidence of stroke is increasing. In China, 1.3 million people have a stroke each year and 75% live with varying degrees of disability as a result of stroke. The predictions for the next two decades suggest a tripling in stroke mortality in Latin America, the Middle East, and sub-Saharan Africa. Read More
U.S. Stroke Incidence
• Each year about 780,000 people experience a new or recurrent stroke. About 600,000 of these are first attacks, and 180,000 are recurrent attacks. (GCNKSS, NINDS, NHLBI.)
• On average, every 40 seconds someone in the United States has a stroke. (AHA computation based on latest available data.)
• Each year, about 60,000 more women than men have a stroke. (GCNKSS, NINDS.)
• Men's stroke incidence rates are greater than women's at younger ages but not at older ages. The male/female incidence ratio was 1.25 at ages 55-64; 1.50 for ages 65-74; 1.07 at ages 75-84 and 0.76 at age 85 and older. (ARIC and CHS studies.)
U.S. Stroke Mortality Rates
• When considered separately from other cardiovascular diseases, stroke ranks No. 3 among all causes of death, behind diseases of the heart and cancer. (NCHS mortality data.)
• On average, every three to four minutes someone dies of a stroke. (NCHS, NHLBI.)
• Among persons ages 45-64, 8 to 12 percent of ischemic strokes and 37 to 38 percent of hemorrhagic strokes result in death within 30 days, according to the ARIC study of the NHLBI.(Stroke. 1999;30:736-743.)
• From 1994-2004, the stroke death rate fell 24.2 percent and the actual number of stroke deaths declined 6.8 percent. (NCHS, CDC. Compressed Mortality File: Underlying Cause of Death;)
U.S. Economic Costs
• The estimated direct and indirect cost of stroke for 2008 is $65.5 billion.
• The mean lifetime cost of ischemic stroke in the United States is estimated at $140,048. This includes inpatient care, rehabilitation and follow-up care necessary for lasting deficits. (All numbers converted to 1999 dollars using the medical component of CPI.) (Stroke. 1996;27:1459-1466.)
Canadian Economic Costs
• Stroke costs the Canadian economy $2.7 billion a year.
• The average acute care costs is about $27,500 per stroke.
• Canadians spend a total of 3 million days in hospital because of stroke. Read More
Stem Cell Therapeutics Corp. Announces Completion of Enrollment in Key Modified REGENESIS Phase IIb Stroke Trial
CALGARY, ALBERTA, Mar 31, 2010 (MARKETWIRE via COMTEX News Network) --
Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE: SSS) announced today that it closed patient enrollment of the modified Phase IIb stroke trial on March 31st, 2010 and will analyze the data as they become available. Using a modified statistical approach the Company will analyze its trial data using the 96 patients that were enrolled.
Dr. Alan Moore, President and CEO, commented as follows:
"The modified REGENESIS-LED Phase IIb stroke trial enrolled 96 patients in six months which is a tremendous achievement. Despite our best recruitment efforts, however, we have not recruited any additional North America patients. The last patient in the trial was recruited at the end of January 2010. Using an alternate method of data analysis, with a proven track record (used in one of t-PA's pivotal phase III studies) will allow us to achieve our endpoint with fewer patients while staying on track with our previously reported time-line. We look forward to receiving the results of this clinical trial for the treatment of stroke patients with NTx(R)-265."
With the modified Phase IIb stroke trial closed, SCT anticipates to complete patient 90 day endpoint assessments by the end of April 2010 with data analysis to follow soon after.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.
For further information on Stem Cell Therapeutics Corp., visit www.stemcellthera.com.
These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President and CEO 403-245-5495 ext.224 amoore@stemcellthera.com Stem Cell Therapeutics Corp. Angelika Goncalves DaSilva Operations Manager 403-245-5495 ext. 221 adasilva@stemcellthera.com www.stemcellthera.com
SOURCE: Stem Cell Therapeutics Corp.
mailto:amoore@stemcellthera.com mailto:adasilva@stemcellthera.com http://www.stemcellthera.com
Copyright 2010 Marketwire, Inc., All rights reserved.
Good morning to you and everyone else. ;)
I didn't get the link from anther stock site. Was just doing a news search.
GLTA
Good morning Karin, thankyou so much for the link
It is few days that I cannot access Stock House Board.
My antivirus is bloking the site
Again thankyou,
Wishing you a good day
janet
Janet...The SSS CEO Dr Alan Moore is quite interesting. We have him playing guitar here:
http://www.stemcellthera.com/Technology.aspx?section=mediacentre
Good to see him enjoying himself. ;)
Stem Cell Therapeutics touts NTx-265 journal paper
2010-03-10 15:22 ET - News Release
Dr. Alan Moore reports
STEM CELL THERAPEUTICS CORP. ANNOUNCES PUBLICATION OF PHASE IIA STROKE DATA
Stem Cell Therapeutics Corp. confirms the acceptance and publication of the paper entitled "The Beta-hCG plus Erythropoietin in Acute Stroke (BETAS) Study," by the journal Stroke on March 8, 2010. This paper was authored by Dr. Steven C. Cramer, from the University of California, Irvine, Dr. David Brown at Hoag Memorial Hospital Presbyterian, New Port Beach, Dr. Michael D. Hill of Foothills Hospital at the University of Calgary and colleagues.
Dr. Allen Davidoff, vice-persident of product development, commented as follows: "The Stroke journal, published by the American Heart Association, is the top journal in the field of stroke research. Stem Cell Therapeutics is pleased to congratulate Dr. Cramer, Dr. Brown and Dr. Hill for their efforts, acceptance and successful publication of this novel study by this highly respected, peer-reviewed journal. Previously this work has only appeared in abstracts. This publication marks another important milestone in the development of NTx-265 and provided the continued evidence of clinical safety and the foundation for the proof of concept study modified REGENESIS."
Welcome to the board. ;)
I look forward to seeing whatever TA you come up with.
Good morning mediascan, thankyou for posting here
Wishing you a very nice weekend
janet
Good morning group.
I was asked by Janet if I could post here.
I typically post TA on stockhouse and add a few comments.
I have been an active trader since 1992.
I believe that trading using TA works in ones favour about 70% of the time.
Fundamentals are worth noting but in my opinion, the charts give you a better idea of where a stock is going, support, resistance levels, etc.
I will just post things as I personally see them and am not a professional.
If my analysis helps some of you in your investment decisions, great.
I will present some TA this weekend.
All the TA does not take into account sudden new releases good or bad. After such a release I would obviously have to reassess what the charts present to me.
Happy Trading all
Mediascan
Hi Karin, it would be nice. I guess all depend what the Co. plans are for the future ????
Have a nice day
janet
I wonder if they ever think of uplisting to the regular tsx?
Thanks for posting. ;)
"Be kinder than necessary, for everyone you meet is fighting some kind of battle."
SSS NEWS:
Headline: Stem Cell Therapeutics Corp. Provides Update on Modified REGENESIS Phase IIb Stroke Trial
Symbol: SSS
CALGARY, ALBERTA--(Marketwire - Feb. 16, 2010) - Stem Cell TherapeuticsCorp. (TSX VENTURE:SSS) ("SCT" or the "Company") announced today thatit will focus the remaining patient enrollment of the modified PhaseIIb stroke trial in Canada and the U.S. and will no longer recruitpatients from India. As standard practice, the Drug Controller Generalof India ("DCGI") limits the amount of patients that participate inclinical trials from companies that are not located in India and SCThas been advised that the stroke trial has reached its limit ofrecruiting patients from India.
This decision by the DCGI was not based on any safety or mortalityconcerns. As announced, the Data Safety Monitoring Board ("DSMB")completed three safety analyses and recommended for the Phase IIb acuteischemic stroke trial to continue as per protocol after each analysis.
Dr. Alan Moore, President and CEO, commented as follows:
"We have moved quickly through the modified REGENESIS Phase IIb stroketrial so far, having enrolled 96 patients in six months, and we willnow be focusing our remaining patient recruitment efforts in Canada andthe U.S. instead of India. Given our historic recruiting rate in NorthAmerica, it now appears unlikely that we will able to complete theenrollment of 128 patients by the end of Q1 2010, as previouslyannounced. We will also be reviewing alternate methods of data analysisto possibly allow an earlier study conclusion prior to recruiting theoriginal goal of 128 patients."
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is apublic biotechnology company (TSX VENTURE:SSS) focused on thedevelopment and commercialization of drug-based therapies to treatcentral nervous system diseases. SCT is a leader in the development oftherapies that utilize drugs to stimulate a patient's own resident stemcells. The Company's programs aim to repair brain and nerve functionlost due to disease or injury. The Company's extensive patent portfolioof owned and licensed intellectual property supports the potentialexpansion into future clinical programs in numerous neurologicaldiseases such as traumatic brain injury, multiple sclerosis,Huntington's disease, Alzheimer's disease, and ALS.
For further information on Stem Cell Therapeutics Corp., visit www.stemcellthera.com.
These securities have not been registered under the United StatesSecurities Act of 1933, as amended, or the securities laws of anystate, and may not be offered or sold within the United States or to,or for the account or benefit of U.S. persons unless an applicableexemption from U.S. registration requirements is available.
Except for historical information, this press release may containforward-looking statements, which reflect the Company's currentexpectation regarding future events. These forward-looking statementsinvolve risk and uncertainties, which may cause but are not limited to,changing market conditions, the successful and timely completion ofclinical studies, the establishment of corporate alliances, the impactof competitive products and pricing, new product development,uncertainties related to the regulatory approval process and otherrisks detailed from time to time in the Company's ongoing quarterly andannual reporting.
Currency Converter:
http://www.bankofcanada.ca/en/rates/converter.html
"Be kinder than necessary, for everyone you meet is fighting some kind of battle."
Good morning locks, but, Janet beat you to this one. ;)
"Be kinder than necessary, for everyone you meet is fighting some kind of battle."
Followers
|
3
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
206
|
Created
|
12/27/07
|
Type
|
Free
|
Moderators |
Stem Cell Therapeutics (SSS.V or SCTPF otc US)
Company Information:
Stem Cell Therapeutics Corp.
Suite 1000, 1520 - 4th Street SW
Calgary, Alberta, Canada T2R1H5
Phone: 403.245.5495
Fax: 403.245.5411
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.
REASONS TO INVEST IN STEM CELL THERAPEUTICS
http://www.stemcellthera.com/IR.aspx
Press Releases:
http://www.stemcellthera.com/NewsAndEvents.aspx?section=pressreleases
Financial Reports:
http://www.stemcellthera.com/IR.aspx?section=reports
Links of importance for those that trade Canadian stocks:
Sedar http://www.sedar.com/homepage_en.htm
TMX. http://www.tmx.com/
TMXmoney http://www.tmxmoney.com/en/index.html
CNW Group Newswire http://www.cnxmarketlink.com/en/index.cgi
Canadian Insider
http://canadianinsider.com/coReport/allTransactions.php?ticker=sss
Currency Converter: http://www.bankofcanada.ca/en/rates/converter.html
-----------------------------------------------------------
FOR FURTHER INFORMATION PLEASE CONTACT:
Stem Cell Therapeutics Corp.
Alan Moore, PhD
President and CEO
(403) 245-5495 ext.224
amoore@stemcellthera.com
or
Stem Cell Therapeutics Corp.
Chloe Douglas-Crampton
Investor Relations
(403) 245-5495 ext. 221
crampton@stemcellthera.com
www.stemcellthera.com
-----------------------------------------------------------
CHART is for Canadian ticker. Remember to adjust for exchange rate.
Currency Converter: http://www.bankofcanada.ca/en/rates/converter.html
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |